ChiCTR2200059342 版本V1.1 版本创建时间2023/02/07 22:38:12 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200059342 

最近更新日期:

Date of Last Refreshed on:

2022-04-28 09:29:51 

注册时间:

Date of Registration:

2022-04-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理批件 子宫内膜容受性检测(ERT)在反复种植失败患者中临床应用的多中心研究

Public title:

A multicenter study of endometrial receptivity test (ERT) in patients with repeated implant failure

注册题目简写:

English Acronym:

研究课题的正式科学名称:

子宫内膜容受性检测(ERT)在反复种植失败患者中临床应用的多中心研究

Scientific title:

A multicenter study of endometrial receptivity test (ERT) in patients with repeated implant failure

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘东云 

研究负责人:

黄国宁 

Applicant:

Liu Dongyun 

Study leader:

Huang Guoning 

申请注册联系人电话:

Applicant telephone:

18680801571

研究负责人电话:

Study leader's
telephone:

13808335727

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

dongyunliu@163.com

研究负责人电子邮件:

Study leader's E-mail:

gnhuang217@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区七星岗金汤街64号

研究负责人通讯地址:

重庆市渝中区七星岗金汤街64号

Applicant address:

64 Jintang Street, Qixinggang, Yuzhong District, Chongqing

Study leader's address:

64 Jintang Street, Qixinggang, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆市妇幼保健院

Applicant's institution:

Chongqing Health Center for Women and Children

研究负责人所在单位:

重庆市妇幼保健院

Affiliation of the Leader:

Chongqing Health Center for Women and Children

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2021)伦审(科)040号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

重庆市妇幼保健院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Chongqing Maternal and Child Health Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-09-25 00:00:00

伦理委员会联系人:

陈勇川

Contact Name of the ethic committee:

Chen Yongchuan

伦理委员会联系地址:

重庆市渝北区龙山路120号

Contact Address of the ethic committee:

120 Longshan Road, Yubei District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆市妇幼保健院

Primary sponsor:

Chongqing Health Center for Women and Children

研究实施负责(组长)单位地址:

重庆市渝中区七星岗金汤街64号

Primary sponsor's address:

64 Jintang Street, Qixinggang, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

渝中

Country:

China

Province:

Chongqing

City:

Yuzhong

单位(医院):

重庆市妇幼保健院

具体地址:

重庆市渝中区七星岗金汤街64号

Institution
hospital:

Chongqing Health Center for Women and Children

Address:

64 Jintang Street, Qixinggang, Yuzhong District, Chongqing

经费或物资来源:

重庆市妇幼保健院

Source(s) of funding:

Chongqing Health Center for Women and Children

研究疾病:

不孕症  

Target disease:

infertility

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究旨在通过一项多中心临床研究,评估子宫内膜容受性检测是否可以作为一种判断子宫内膜种植窗的方法,通过比较子宫内膜容受性检测指导的个体化胚胎移植与传统胚胎移植方案的妊娠结局,探讨子宫内膜容受性检测改善反复种植失败患者临床妊娠结局的有效性。同时为该方法在临床上的预期用途、适应症及适用人群的确定提供临床数据支撑。  

Objectives of Study:

Of this study is to pass a multi-center clinical research, assess whether the receptivity of endometrium detection can be used as a judge endometrial planting window method, by comparing the receptivity of endometrium detection guide individual embryo transfer pregnancy outcome and traditional embryo transfer scheme, discusses the receptivity of endometrium testing to improve the effectiveness of clinical pregnancy outcome in patients with repeated planting failure. At the same time, it provides clinical data support for the expected use, indication and suitable population of this method in clinical practice.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)女方年龄 25-36 岁;
2)BMI 指数 18-25 kg/m2;
3)不明原因反复种植失败(经历 3 次及 3 次以上胚胎移植或累积移植胚胎数量≥4 枚未获临床妊娠,且无明确种植失败原因者);
4)有可移植冷冻囊胚(≥3BB);
5)雌孕激素替代治疗(HRT),内膜转化日内膜厚度≥7mm。

Inclusion criteria

1) The woman is 25-36 years old;
2) BMI 18-25 kg/m2;
3) Repeated implantation failure for unknown reasons (those who have undergone 3 or more embryo transfers or have accumulated more than 4 embryos without clinical pregnancy and have no clear reasons for implantation failure);
4) Transplantable frozen blastocysts (≥3BB);
5) Estrogen progesterone replacement therapy (HRT), endometrial thickness ≥7mm on endometrial transformation day.

排除标准:

1)男女双方或一方染色体异常(不包括染色体多态);
2)已行 PGT 的患者;
3)可能影响着床的子宫病变(包括宫腔粘连史、粘膜下肌瘤、>4cm 肌壁间肌瘤、子宫腺肌病);
4)有输卵管积水且未行输卵管近端结扎者;
5)子宫畸形;
6)反复自然流产(2 次或 2 次以上在妊娠 28 周之前的胎儿丢失);
7)已知胚胎因素导致植入失败患者;
8)严重的内外分泌疾病;
9)其他研究者认为不适合参加本研究的任何情况。

Exclusion criteria:

1) Chromosomal abnormalities of both male and female (excluding chromosomal polymorphism);
2) Patients with PGT;
3) Uterine lesions that may affect implantation (including history of intrauterine adhesion, submucosal myoma, intramural myoma > 4cm, adenomyosis);
4) Hydrosalpinx without proximal tubal ligation;
5) Uterine malformation;
6) Repeated spontaneous abortion (2 or more fetal loss before 28 weeks of gestation);
7) Patients with implant failure due to known embryonic factors;
8) serious internal and external secretory diseases;
9) Any circumstances deemed unsuitable for participation in this study by other researchers.

研究实施时间:

Study execute time:

From 2020-10-01 00:00:00 To 2022-10-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-04-12 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

294

Group:

Experimental group

Sample size:

干预措施:

子宫内膜容受性检测后根据结果进行胚胎移植

干预措施代码:

Intervention:

Embryo transfer after endometrial receptivity testing according to the results

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

渝中 

Country:

China

Province:

Chongqing

City:

Yuzhong

单位(医院):

重庆市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Chongqing Health Center for Women and Children

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都市妇女儿童中心医院 

单位级别:

三甲 

Institution
hospital:

Chengdu Women and Children's Central Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

重庆 

市(区县):

渝中 

Country:

China

Province:

Chongqing

City:

Yuzhong

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省第二人民医院 

单位级别:

三甲 

Institution
hospital:

Second People's Hospital of Guangdong Province

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属同济医院 

单位级别:

三甲 

Institution
hospital:

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

华中科技大学同济医学院附属协和医院 

单位级别:

三甲 

Institution
hospital:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

甘肃 

市(区县):

兰州 

Country:

China

Province:

Gansu

City:

Lanzhou

单位(医院):

兰州大学第一医院 

单位级别:

三甲 

Institution
hospital:

First Hospital of Lanzhou University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

静安 

Country:

China

Province:

Shanghai

City:

Jing'an

单位(医院):

上海市第一妇婴保健院 

单位级别:

三甲 

Institution
hospital:

Shanghai First Maternal and Infant Health Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南 

市(区县):

郑州 

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

郑州大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅医院 

单位级别:

三甲 

Institution
hospital:

Xiangya Hospital Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学附属第六医院 

单位级别:

三甲 

Institution
hospital:

The Sixth Affiliated Hospital of Sun Yat-sen University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

成都西囡妇科医院 

单位级别:

三甲 

Institution
hospital:

Chengdu Xinan Gynecological Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

宫内胚胎种植率

指标类型:

主要指标

Outcome:

Rate of intrauterine embryo implantation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

宫内临床妊娠率

指标类型:

次要指标

Outcome:

Intrauterine clinical pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

继续妊娠率

指标类型:

次要指标

Outcome:

Continued pregnancy rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

宫外孕发生率

指标类型:

次要指标

Outcome:

Incidence of ectopic pregnancy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

自然流产率(12 周以内)

指标类型:

次要指标

Outcome:

Spontaneous abortion rate (less than 12 weeks)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

子宫内膜组织

组织:

子宫腔

Sample Name:

Endometrial tissue

Tissue:

Uterine cavity

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 25 years
最大 Max age 36 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果发表后6个月,向研究者联系索取原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

6 months after publication of results and Contact the researcher for raw data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表及电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-04-28 09:29:18